Blinklab Limited · ASX:BB1
Blinklab — Investor Presentation (December 2025)
25 slides from Blinklab's investor presentation, Dec 2, 2025
Slide 1: Early and Accurate Diagnosis of Autism and ADHD
(ASX:BB1) For personal use only Early and Accurate Diagnosis of Autism and ADHD Introducing an AI-powered smartphone platform for neurological testing December 2025, BlinkLab Ltd
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by BlinkLab Limited (ACN 652 901 703) (BlinkLab or Company) and contains background information about For personal use only BlinkLab’s current operations at the date of this presentation. The presentation is in summary form and does not purport to be al
Slide 3: Corporate Snapshot
Corporate Snapshot Next-Generation Digital Solutions for Neurodevelopmental Health CAPITAL STRUCTURE - ASX:BB1 For personal use only Shares on Issue 125.7M Options on Issue 44.5M Performance Rights 3.0M Founders’/ Directors’ percentage ±24% Market Cap (28 November 2025) $114M Cash (30 September - Qu
Slide 4: What is Autism?
What is Autism? For personal use only “Neurodevelopmental condition that affects how the brain processes sensory information.” Autism can impact: • Social development • Language and communication • Sensorimotor development • Behavior and interests
Slide 5: USA: Economic burden of autism was $700B in 2024
USA: Economic burden of autism was $700B in 2024 "The economic burden is significant and alarming” 1 For personal use only Ø Prevalence has grown up to 2-4% among children2 Ø Autism healthcare expenses are soaring3 • Costs for an autism diagnostic evaluation: $1,000 to $7,000 • Lifetime cost for ind
Slide 6: Australia: NDIS payments for autism is over A$9.9B in 2025
Australia: NDIS payments for autism is over A$9.9B in 2025 Autism accounts for 41% of all NDIS participants, making it the most common disability. For personal use only Data extracted and visualized by BlinkLab, based on information from the National Disability Insurance Scheme (NDIS) - https://data
Slide 7: Consensus: Early diagnosis and intervention helps children
Consensus: Early diagnosis and intervention helps children to develop crucial skills and reduces long-term support needs and costs For personal use only Ø Early detection and diagnosis is crucial 1-5 The American Academy of Pediatrics recommends that all children must be screened for autism at ages
Slide 8: Autism diagnosis is expensive, inefficient, and often late
Autism diagnosis is expensive, inefficient, and often late The costly labor and time-intensive diagnostic evaluations are unnecessary for many children. For personal use only 1-3 years of uncertainty for family and child ? ? Occupational Parents Primary Care Neuro- Late autism Late Concerned or GP P
Slide 9: BlinkLab's digital solution accelerates path to diagnosis
BlinkLab’s digital solution accelerates path to diagnosis The costly labor and time-intensive diagnostic evaluations are unnecessary for many children. For personal use only Diagnosis in weeks to months ? ? Parents Primary Care Neuro- Early autism Early and personalized intervention Concerned or GP
Slide 10: BlinkLab's AI-enabled Smartphone-based Assessment
For personal use only BlinkLab’s AI-enabled Smartphone-based Assessment
Slide 11: Our patented solution: Neuroscience on a smartphone
Our patented solution: Neuroscience on a smartphone For personal use only Minuscule facial reflexes, evoked by our app, Evokes Facial Reflexes generate a digital biomarker for autism. By presenting visual and auditory stimuli during smartphone use. Computer Vision Facial features are tracked on the
Slide 12: Beyond blinks: Tracking of vocal responses and hand/head movements
Beyond blinks: Tracking of vocal responses and hand/head movements as objective markers for autism For personal use only Screen avoidance Head rotations Side eye Pupil range Postural stability Headphone touches Mouth openings Vocalizations Image used with permission Gultig et al., 2025; https://www.
Slide 13: Pilot Study Confirms High Diagnostic Accuracy and Readiness for FDA Trial
Pilot Study Confirms High Diagnostic Accuracy and Readiness for FDA Trial For personal use only ASX Announcement 22 October 2025 Highlights: Ø Pilot Study Completion: BlinkLab has successfully completed its U.S. Pilot Study of the Dx 1 diagnostic device, involving 485 children. Ø Ø Strong Diagnostic
Slide 14: Why not 100% sensitivity and 100% specificity?
Why not 100% sensitivity and 100% specificity? The ‘ceiling’ for BlinkLab Dx 1 is 85-90% for both sensitivity and specificity, because... For personal use only Ø Diagnostic Stability 1st Evaluation Re-evaluation Few years later... “BlinkLab’s sensitivity and Autism clinical diagnostic stability is e
Slide 15: BlinkLab Outperforms FDA-approved Digital Peers
BlinkLab Outperforms FDA-approved Digital Peers We are leaders in the digital autism diagnostics space For personal use only Sensitivity 84% 52%* 71% Specificity 85% 19%* 81% Smartphone-based Yes Yes No FDA approval No - 510(k) Yes - De Novo Yes - 510(k) * Calculated over all study completers (Cogno
Slide 16: Study Design and Timeline for 510(k) Regulatory Trial for Dx 1
Study Design and Timeline for 510(k) Regulatory Trial for Dx 1 Prospective, multicenter in US, double-blinded, within-subject comparison study. For personal use only Enroll children between 2-11 Q4 2024 - CRO assigned years and sign ICF - IRB approval for Pilot Study - First pre-submission meeting w
Slide 17: BlinkLab is onboarding Top-Tier hospitals in the US
BlinkLab is onboarding Top-Tier hospitals in the US to participate in the 510(k) autism study For personal use only
Slide 18: We are experts in science, tech and commercialization
We are experts in science, tech and commercialization For personal use only Henk-Jan Boele, CEO Anton Uvarov, COO Bas Koekkoek, CSO Peter Boele, CTO Executive director MD, PhD, Entrepreneur and MBA, PhD, Biotechnology Analyst PhD, Assistant Professor of MA, PhD candidate, Erasmus MC neuroscientist a
Slide 19: We are backed up by an expert advisory board
We are backed up by an expert advisory board For personal use only Company Chairman Company Director Company Director Scientific advisor Scientific advisor Scientific advisor Brian Leedman Jane Morgan Richard Hopkins Prof. Samuel Wang Prof. Chris De Zeeuw Prof. Javier Medina Experienced Chairman and
Slide 20: Our AI technology detects autism and ADHD
Our AI technology detects autism and ADHD For personal use only BlinkLab precisely measures sensory sensitivity in people with autism and ADHD.
Slide 21: Catalysts and milestones for Dx autism and Dx ADHD models
Catalysts and milestones for Dx 1 autism and Dx 2 ADHD models News pipeline on updates our regulatory studies on autism and ADHD and new partnerships use only BlinkLab Dx 1 – Autism Model Calendar Year BlinkLab Dx 2 – ADHD model Calendar Year Pilot Study Release of Pilot Study Results 4Q 2025 Comple
Slide 22: BlinkLab's GTM strategy follows a traditional medical adoption curve
BlinkLab’s GTM strategy follows a traditional medical adoption curve Research -> Autism Specialist -> Primary Care (GP/PCP) * The GTM plan shown on this slide applies to Dx 1 in the US market only. The GTM approach for Dx 2 and/or non-US markets will follow a similar structure. 2021-24 2025 2026 202
Slide 23: Intellectual property
Intellectual property Our patents prohibit other parties to conduct neurometric testing using mobile devices. For personal use only BlinkLab has consistently prioritized the development We are represented by the US-based law firm, Meagher Our portfolio comprises patents filed both by Princeton and p
Slide 24: Other Applications for BlinkLab and Trials Underway
Other Applications for BlinkLab and Trials Underway Ø European ADHD Study ○ Collaborator: Mental Care Group For personal use only ○ Goal: Develop BlinkLab Dx 2 - ADHD Model ○ Status: Recruiting - 300 children will have completed all testing in mid-Q4 ASX Announcement, 30th Jul 2024; BlinkLab Partner
Slide 25: For further information please contact
ASX:BB1 For personal use only For further information please contact: Henk-Jan Boele, MD, PhD Brian Leedman Cofounder and CEO Non-Executive Chairman henkjan@blinklab.org brian@blinklab.org M: +31 (0) 611 132 247 M: +61 (0) 412 281 780 info@blinklab.org @BlinkLab.App @Blink_Lab BlinkLab Limited (ASX: